StockData
Nkarta, Inc. logo

Nkarta, Inc. (NKTX) stock

NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$1.14+0.01 (+1.34%)

Close on Nov 20, 2026Market cap $81.29MP/E –Yield 0.00%

Nkarta net income

Net income is the profit left for shareholders after every expense, interest and tax.

Nkarta's net income for the twelve months ending Jun 30, 2026 was -$117.32M. For fiscal 2025 it was -$104.08M. The highest annual figure on record is -$21.08M in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$104.08M–
FY2024Dec 31, 2024-$108.79M–
FY2023Dec 31, 2023-$117.50M–
FY2022Dec 31, 2022-$113.84M–
FY2021Dec 31, 2021-$86.08M–
FY2020Dec 31, 2020-$91.36M–
FY2019Dec 31, 2019-$21.08M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$40.37M–
Q1 FY2026Mar 31, 2026-$27.83M–
Q4 FY2025Dec 31, 2025-$27.41M–
Q3 FY2025Sep 30, 2025-$21.72M–
Q2 FY2025Jun 30, 2025-$22.98M–
Q1 FY2025Mar 31, 2025-$31.98M–
Q4 FY2024Dec 31, 2024-$25.94M–
Q3 FY2024Sep 30, 2024-$28.34M–
Q2 FY2024Jun 30, 2024-$24.99M–
Q1 FY2024Mar 31, 2024-$29.52M–
Q4 FY2023Dec 31, 2023-$27.75M–
Q3 FY2023Sep 30, 2023-$25.65M–
Q2 FY2023Jun 30, 2023-$33.29M–
Q1 FY2023Mar 31, 2023-$30.82M–
Q4 FY2022Dec 31, 2022-$32.58M–
Q3 FY2022Sep 30, 2022-$28.35M–
Q2 FY2022Jun 30, 2022-$26.92M–
Q1 FY2022Mar 31, 2022-$25.99M–
Q4 FY2021Dec 31, 2021-$22.81M–
Q3 FY2021Sep 30, 2021-$22.35M–
Q2 FY2021Jun 30, 2021-$21.54M–
Q1 FY2021Mar 31, 2021-$19.37M–
Q4 FY2020Dec 31, 2020-$17.90M–
Q3 FY2020Sep 30, 2020-$13.69M–
Q2 FY2020Jun 30, 2020-$51.07M–
Q1 FY2020Mar 31, 2020-$8.71M–
Q4 FY2019Dec 31, 2019-$10.49M–
Q3 FY2019Sep 30, 2019-$2.67M–
Q2 FY2019Jun 30, 2019-$4.84M–
Q1 FY2019Mar 31, 2019-$3.08M–

More Nkarta figures

See a number that looks wrong?